Skip to main content

Healthcare startups

Healthcare startups to see surge in M&A as funding dries up


Healthcare startups are set for increased mergers and acquisitions in 2025, driven by cash-strapped firms, declining revenue multiples, and investor caution, particularly in diagnostics and care delivery.

Healthcare startups are poised for increased mergers and acquisitions (M&A) in the current calendar year as revenue multiples decline and cash-strapped firms struggle in a tight funding market, according to early-stage healthcare-focused investment firm W Health Ventures.

The consolidation wave is expected to be most pronounced in diagnostics, where large pathology chains are likely to acquire smaller, hyperlocal labs and radiology centres to expand their geographic reach. Care delivery companies specialising in single fields such as IVF, eyecare, and oncology may also see exits, with promoters selling to private equity-backed platforms, said Namit Chugh, principal at W Health Ventures.

Investor caution has left many healthcare startups strapped for cash. Funding in the sector remained at nearly half of the average levels seen in 2021 and 2022, as backers waited for firms to achieve product-market fit before committing capital. As a result, 70% of early-stage healthcare startups have not raised a funding round since then, W Health Ventures said in a report on India’s healthcare ecosystem.

“A large number of healthcare startups with low cash reserves will become lucrative acquisition targets,” Chugh said. Late-stage, well-funded startups and global private equity firms are expected to drive most of the deal-making. With revenue multiples in private markets down by 60% from 2022 levels, acquisitions are now significantly more attractive for buyers.

Earlier this year, Wysa, an AI-powered mental health chatbot backed by W Health Ventures, merged with US-based April Health to integrate AI-driven mental health support into primary care, signaling a trend of strategic tie-ups.

Among different M&A models, acqui-hiring —where talent is acquired rather than just the business — could gain traction, offering startups an opportunity to expand service lines while securing high-quality, experienced teams. “We foresee more such transactions in 2025, including acquisitions via our portfolio companies,” W Health Ventures stated.

While consolidation accelerates in diagnostics and care delivery, quick-commerce healthcare ventures may struggle. Pharmacy quick-commerce startups face intensifying competition, which could lead to aggressive cash burn through speed and discount wars against local pharmacies. Inventory management challenges and regulatory compliance hurdles further compound the risks.

“By the end of 2025, we anticipate that at least a few q-commerce healthcare players will lose this race,” the report said. “The real question remains — aside from critical patients, does anyone really need medicines in ten minutes?”

Since 2021, W Health Ventures has been investing from its $100-million Fund I in startups such as BeatO, a personalised diabetes management platform; Mylo, a parenting community; AI-guided mental health firm Wysa; and Reveal Healthtech, which provides AI and engineering services to the healthcare industry. The firm is currently raising its second fund, targeting another $100 million.

Healthcare, medical research, patient care, public health, disease prevention, clinical trials, health technology, digital health, telemedicine, medical innovation, epidemiology, healthcare policy, mental health, precision medicine, biomedical science, health informatics, global health, personalized medicine, healthcare management, regenerative medicine,

#Healthcare #MedicalResearch #PatientCare #PublicHealth #DiseasePrevention #ClinicalTrials #HealthTech #DigitalHealth #Telemedicine #MedicalInnovation #Epidemiology #HealthcarePolicy #MentalHealth #PrecisionMedicine #BiomedicalScience #HealthInformatics #GlobalHealth #PersonalizedMedicine #HealthcareManagement #RegenerativeMedicine

International Conference on Genetics and Genomics of Diseases

Visit: genetics-conferences.healthcarek.com

Award Nomination: genetics-conferences.healthcarek.com/award-nomination/?ecategory=Awards&rcategory=Awardee

Award registration: genetics-conferences.healthcarek.com/award-registration/

For Enquiries: contact@healthcarek.com

Get Connected Here
---------------------------------
---------------------------------
in.pinterest.com/Dorita0211
twitter.com/Dorita_02_11_
facebook.com/profile.php?id=61555903296992
instagram.com/p/C4ukfcOsK36
genetics-awards.blogspot.com/
youtube.com/@GeneticsHealthcare

Comments

Post a Comment

Popular posts from this blog

Fruitful innovation

Fruitful innovation: Transforming watermelon genetics with advanced base editors The development of new adenine base editors (ABE) and adenine-to-thymine/ guanine base editors (AKBE) is transforming watermelon genetic engineering. These innovative tools enable precise A:T-to-G and A:T-to-T base substitutions, allowing for targeted genetic modifications. The research highlights the efficiency of these editors in generating specific mutations, such as a flowerless phenotype in ClFT (Y84H) mutant plants. This advancement not only enhances the understanding of gene function but also significantly improves molecular breeding, paving the way for more efficient watermelon crop improvement. Traditional breeding methods for watermelon often face challenges in achieving desired genetic traits efficiently and accurately. While CRISPR/Cas9 has provided a powerful tool for genome editing, its precision and scope are sometimes limited. These limitations highlight the need for more advanced gene-e...
Post a Comment
Read more

Genetic factors with clinical trial stoppage

Genetic factors associated with reasons for clinical trial stoppage Many drug discovery projects are started but few progress fully through clinical trials to approval. Previous work has shown that human genetics support for the therapeutic hypothesis increases the chance of trial progression. Here, we applied natural language processing to classify the free-text reasons for 28,561 clinical trials that stopped before their endpoints were met. We then evaluated these classes in light of the underlying evidence for the therapeutic hypothesis and target properties. We found that trials are more likely to stop because of a lack of efficacy in the absence of strong genetic evidence from human populations or genetically modified animal models. Furthermore, certain trials are more likely to stop for safety reasons if the drug target gene is highly constrained in human populations and if the gene is broadly expressed across tissues. These results support the growing use of human genetics to ...
Post a Comment
Read more

Genetics study on COVID-19

Large genetic study on severe COVID-19 Bonn researchers confirm three other genes for increased risk in addition to the known TLR7 gene Whether or not a person becomes seriously ill with COVID-19 depends, among other things, on genetic factors. With this in mind, researchers from the University Hospital Bonn (UKB) and the University of Bonn, in cooperation with other research teams from Germany, the Netherlands, Spain and Italy, investigated a particularly large group of affected individuals. They confirmed the central and already known role of the TLR7 gene in severe courses of the disease in men, but were also able to find evidence for a contribution of the gene in women. In addition, they were able to show that genetic changes in three other genes of the innate immune system contribute to severe COVID-19. The results have now been published in the journal " Human Genetics and Genomics Advances ". Even though the number of severe cases following infection with the SARS-CoV-...
Post a Comment
Read more